Synapse - Jonathan Rosenberg

Results (520)

EAU-ESMO consensus statements on the management of advanced and variant bladder cancer - An international collaborative multi-stakeholder effort: Under the auspices of the EAU and ESMO Guidelines Committees†

Guidelines

Horwich, A.; Babjuk, M.; Bellmunt, J.; Bruins, H. M.; De Reijke, T. M.; De Santis, M.; Gillessen, S.; James, N.; Maclennan, S.; Palou, J.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Sitravatinib in combination with nivolumab demonstrates clinical activity in platinum-experienced patients with urothelial carcinoma (UC) who progressed on prior immune checkpoint inhibitor (CPI)

Meeting Abstract

Msaouel, P.; Siefker-Radtke, A.; Sweis, R.; Mortazavi, A.; Vogelzang, N.; Vaishampayan, U.; Bradley, T.; Bupathi, M.; Nordquist, L.; Shaffer, D.; more...
Journal for ImmunoTherapy of Cancer (2019)

Fulltext@MSK | Save

Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)

Meeting Abstract

Hoffman-Censits, J.; Rosenberg, J. E.; van Der Heijden, M.; Dreicer, R.; Perez Gracia, J. L.; Petrylak, D. P.; Retz, M. M.; Sabbatini, R.; Naglieri, E.; Caserta, C.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma

Meeting Abstract

Hoimes, C. J.; Rosenberg, J. E.; Srinivas, S.; Petrylak, D. P.; Milowsky, M.; Merchan, J. R.; Bilen, M. A.; Gupta, S.; Carret, A. S.; Yuan, N.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC)

Meeting Abstract

Pal, S. K.; Bajorin, D. F.; Hoffman-Censits, J. H.; Quinn, D. I.; Petrylak, D. P.; Galsky, M. D.; Vaishampayan, U. N.; De Giorgi, U.; Gupta, S.; Burris, H. A.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Quality of life of metastatic urothelial cancer (mUC) patients treated with enfortumab vedotin (EV) following platinum-containing chemotherapy and a checkpoint inhibitor (CPI): Data from EV-201 cohort 1

Meeting Abstract

McGregor, B. A.; O'Donnell, P. H.; Balar, A.; Petrylak, D. P.; Rosenberg, J. E.; Yu, E.; Quinn, D. I.; Shah, S. N.; Pinelli, J.; Hepp, Z.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy

Journal Article

Rosenberg, J. E.; O'Donnell, P. H.; Balar, A. V.; McGregor, B. A.; Heath, E. I.; Yu, E. Y.; Galsky, M. D.; Hahn, N. M.; Gartner, E. M.; Pinelli, J. M.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Propensity-matched analysis of patient-reported outcomes for neoadjuvant chemotherapy prior to radical cystectomy

Journal Article

Feuerstein, M. A.; Goldstein, L.; Reaves, B.; Sun, A.; Goltzman, M.; Morganstern, B. A.; Shabsigh, A.; Bajorin, D. F.; Rosenberg, J. E.; Donat, S. M.; more...
World Journal of Urology (2019)

Fulltext@MSK | Save

EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors